IMTX – Immatics N.V
Immatics N.V.IMTX
$9.16Name : Immatics N.V.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,251,926,144.00
EPSttm : -1.97
Immatics N.V.
$9.16
0.65%$0.06
IMTX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
4.28
Margin Of Safety %
Put/Call OI Ratio
0.09
EPS Next Q Diff
EPS Last/This Y
-0.08
EPS This/Next Y
0.05
Price
9.15
Target Price
18.44
Analyst Recom
1
Performance Q
-12.76
Upside
-379.6%
Beta
1.35
Ticker: IMTX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-05-11 | IMTX | 11.54 | 0.22 | 999.99 | 366 |
| 2026-05-12 | IMTX | 11.35 | 0.22 | 999.99 | 366 |
| 2026-05-13 | IMTX | 10.79 | 0.22 | 999.99 | 367 |
| 2026-05-14 | IMTX | 11.18 | 0.25 | 0.00 | 375 |
| 2026-05-15 | IMTX | 10.89 | 0.08 | 0.00 | 980 |
| 2026-05-18 | IMTX | 10.6 | 0.05 | 0.00 | 944 |
| 2026-05-19 | IMTX | 10.71 | 0.05 | 0.00 | 948 |
| 2026-05-20 | IMTX | 11.23 | 0.05 | 0.00 | 948 |
| 2026-05-21 | IMTX | 11.06 | 0.05 | 0.00 | 948 |
| 2026-05-22 | IMTX | 11.59 | 0.05 | 10.00 | 954 |
| 2026-05-26 | IMTX | 11.21 | 0.06 | 0.00 | 959 |
| 2026-05-27 | IMTX | 11.39 | 0.06 | 0.00 | 966 |
| 2026-05-28 | IMTX | 11.43 | 0.06 | 999.99 | 966 |
| 2026-05-29 | IMTX | 11.51 | 0.06 | 0.00 | 967 |
| 2026-06-02 | IMTX | 10.05 | 0.08 | 0.42 | 1000 |
| 2026-06-03 | IMTX | 10.21 | 0.08 | 0.42 | 1000 |
| 2026-06-04 | IMTX | 10.19 | 0.08 | 0.42 | 1000 |
| 2026-06-05 | IMTX | 9.79 | 0.09 | 999.99 | 1013 |
| 2026-06-08 | IMTX | 9.23 | 0.09 | 999.99 | 1013 |
| 2026-06-09 | IMTX | 9.16 | 0.09 | 999.99 | 1014 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-05-11 | IMTX | 11.54 | -19.5 | - | -1.75 |
| 2026-05-12 | IMTX | 11.36 | -19.5 | - | -1.75 |
| 2026-05-13 | IMTX | 10.79 | -19.5 | - | -1.75 |
| 2026-05-14 | IMTX | 11.18 | -19.5 | - | -1.75 |
| 2026-05-15 | IMTX | 10.89 | -19.5 | - | -1.75 |
| 2026-05-18 | IMTX | 10.60 | 31.8 | - | -2.07 |
| 2026-05-19 | IMTX | 10.71 | 31.8 | - | -2.07 |
| 2026-05-20 | IMTX | 11.22 | 23.6 | - | -1.91 |
| 2026-05-21 | IMTX | 11.07 | 23.6 | - | -1.91 |
| 2026-05-22 | IMTX | 11.60 | 29.8 | - | -1.91 |
| 2026-05-26 | IMTX | 11.19 | 28.6 | - | -1.95 |
| 2026-05-27 | IMTX | 11.39 | 28.6 | - | -1.95 |
| 2026-05-28 | IMTX | 11.43 | 28.6 | - | -1.95 |
| 2026-05-29 | IMTX | 11.47 | 28.6 | - | -1.95 |
| 2026-06-01 | IMTX | 11.13 | 28.6 | - | -1.95 |
| 2026-06-02 | IMTX | 10.02 | 28.6 | - | -1.95 |
| 2026-06-03 | IMTX | 10.20 | 28.6 | - | -1.95 |
| 2026-06-04 | IMTX | 10.19 | 28.6 | - | -1.95 |
| 2026-06-05 | IMTX | 9.81 | 28.7 | - | -1.95 |
| 2026-06-08 | IMTX | 9.21 | 28.7 | - | -1.95 |
| 2026-06-09 | IMTX | 9.15 | 28.7 | - | -1.95 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-05-11 | IMTX | 0.00 | 6.31 | 4.56 |
| 2026-05-12 | IMTX | 0.00 | 6.31 | 4.59 |
| 2026-05-13 | IMTX | 0.00 | 6.31 | 4.59 |
| 2026-05-14 | IMTX | 0.00 | 6.31 | 4.59 |
| 2026-05-15 | IMTX | 0.00 | 6.31 | 4.59 |
| 2026-05-18 | IMTX | 0.00 | 2.69 | 4.59 |
| 2026-05-19 | IMTX | 0.00 | 2.69 | 4.59 |
| 2026-05-20 | IMTX | 0.00 | 2.69 | 4.59 |
| 2026-05-21 | IMTX | 0.00 | 2.69 | 4.59 |
| 2026-05-22 | IMTX | 0.00 | 2.69 | 4.59 |
| 2026-05-26 | IMTX | 0.00 | 5.10 | 4.60 |
| 2026-05-27 | IMTX | 0.00 | 5.10 | 4.60 |
| 2026-05-28 | IMTX | 0.00 | 5.10 | 4.28 |
| 2026-05-29 | IMTX | 0.00 | 5.10 | 4.28 |
| 2026-06-02 | IMTX | 0.00 | 5.25 | 4.28 |
| 2026-06-03 | IMTX | 0.00 | 5.25 | 4.28 |
| 2026-06-04 | IMTX | 0.00 | 5.25 | 4.28 |
| 2026-06-05 | IMTX | 0.00 | 5.25 | 4.28 |
| 2026-06-08 | IMTX | 0.00 | 5.24 | 4.28 |
| 2026-06-09 | IMTX | 0.00 | 5.24 | 4.28 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.5
Avg. EPS Est. Current Quarter
-0.48
Avg. EPS Est. Next Quarter
-0.5
Insider Transactions
Institutional Transactions
5.24
Beta
1.35
Average Sales Estimate Current Quarter
12
Average Sales Estimate Next Quarter
11
Fair Value
Quality Score
28
Growth Score
32
Sentiment Score
46
Actual DrawDown %
43.8
Max Drawdown 5-Year %
-77.4
Target Price
18.44
P/E
Forward P/E
PEG
P/S
28.34
P/B
2.38
P/Free Cash Flow
EPS
-1.97
Average EPS Est. Cur. Y
-1.95
EPS Next Y. (Est.)
-1.89
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-572.25
Relative Volume
1.01
Return on Equity vs Sector %
-74.5
Return on Equity vs Industry %
-58.4
EPS 1 7Days Diff
EPS 1 30Days Diff
-1.95
EBIT Estimation
◆
IMTX
Healthcare
$9.16
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
31.4
Range 1M
5.4%
Sup Dist
2.5%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-7.1%
EPS NY
2%
52W%
55.8%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+101.3% upside
Upside
+101.3%
Quality
28
Immatics N.V.Sector: Healthcare
Industry: Biotechnology
Employees: 589
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
IMTX
Latest News
—
Caricamento notizie per IMTX…
stock quote shares IMTX – Immatics N.V Stock Price stock today
news today IMTX – Immatics N.V stock forecast ,stock prediction 2023 2024 2025
marketwatch IMTX – Immatics N.V yahoo finance google finance
stock history IMTX – Immatics N.V invest stock market
stock prices IMTX premarket after hours
ticker IMTX fair value insiders trading